The Lancet Diabetes & Endocrinology

Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

By Daisuke Yabe, Toshihiko Shiraiwa, Hiroyuki Ugai, Masakazu Takeuchi, Ryo Suzuki

Randomised trial in 401 peopleInterventions

52 weeks, multicentre, registered NCT06010004

The paper

Daisuke Yabe, Toshihiko Shiraiwa, Hiroyuki Ugai, Masakazu Takeuchi, Ryo Suzuki

Kyoto University; Tokyo Medical University

The Lancet Diabetes & Endocrinology, 17 Aug 2026

doi.org/10.1016/s2213-8587(26)00138-5 PubMed 42607698

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression